Skip to main content

Share story

Infrastructure Products

Honda commits $3B to Ohio assembly plant focused on hybrids

Honda commits $3B to Ohio assembly plant focused on hybrids Image: Primary
Honda said Monday it will invest $3B in a new Ohio vehicle assembly plant with capacity for up to 240,000 vehicles a year. Production is scheduled to begin in 2029 at the site between its Marysville and East Liberty factories. The plant will focus on hybrids but can also build petrol and electric cars. Honda says it will create more than 2,000 jobs and raise its US capacity to about 1.3 million vehicles annually. The investment follows its cancellation of the North American EV lineup in March and indefinite suspension of an $11B Canadian EV and battery project in May.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from The Next Web and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Infrastructure AI
Infrastructure AI

Anthropic buys $3.4 billion in natural gas generators

Anthropic is spending $3.4 billion on Caterpillar natural gas generators capable of producing up to 1.7 gigawatts of electricity, TechCrunch reports, citing the Financial Times.

Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital
Capital

Coframe raises $25 million for automated website experiments

Coframe announced a $25 million Series A co-led by Khosla Ventures and Hanabi Capital, bringing its total funding to $35 million. The company develops software that generates and tests variations of websites, landing pages and advertisements.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.